September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Twelve-month treatment with intravitreal dexamethasone implant for diabetic macular edema
Author Affiliations & Notes
  • Valentina Sarao
    Medical and Biological Sciences - Ophthalmology, University of Udine, Udine, Italy
    Istituto Europeo di Microchirurgia Oculare-IEMO, Udine, Italy
  • Daniele Veritti
    Medical and Biological Sciences - Ophthalmology, University of Udine, Udine, Italy
    Istituto Europeo di Microchirurgia Oculare-IEMO, Udine, Italy
  • Paolo Lanzetta
    Medical and Biological Sciences - Ophthalmology, University of Udine, Udine, Italy
    Istituto Europeo di Microchirurgia Oculare-IEMO, Udine, Italy
  • Footnotes
    Commercial Relationships   Valentina Sarao, None; Daniele Veritti, None; Paolo Lanzetta, Alcon (C), Alimera (C), Allergan (C), Bausch&Lomb (C), Bayer (P), Genentech (C), Iridex Co (P), Lupin (C), Lutronic (C), Novartis Pharma AG (C), Roche (C), Teva (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 3253. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Valentina Sarao, Daniele Veritti, Paolo Lanzetta; Twelve-month treatment with intravitreal dexamethasone implant for diabetic macular edema. Invest. Ophthalmol. Vis. Sci. 2016;57(12):3253.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy and safety of 12-month intravitreal dexamethasone implant for the treatment of diabetic macular edema (DME).

Methods : The present study is a retrospective chart review of eyes affected by DME that received a 700-μg dexamethasone implant and were monthly monitored with best-corrected visual acuity (BCVA) measurement, complete ophthalmologic evaluation and swept source optical coherence tomography (SS-OCT) imaging for at least 12 months. Re-treatment was performed at investigator discretion on the basis of functional or morphological criteria. The primary efficacy outcome was a change in BCVA (logMAR). Secondary outcomes included reduction in central retinal thickness (CRT) and number of injections administered. The incidence of ocular and non-ocular adverse events was recorded.

Results : The study included 20 eyes with DME. A significant improvement of BCVA and CRT was observed during the study period (p=0.001 and p<0.0001, respectively). At 12 months visual acuity (±SD) improved on average by 0.15 (±0.2) logMAR (n.s.) and mean reduction in CRT (±SD) was 150 (±116) μm (P<0.01). Five eyes (25%) only receive the first treatment during one year of follow-up. Twelve patients (60%) experienced a recurrence of DME between 4 and 6 months after the first injection and required an additional treatment. Patients received on average 2.6 treatments in 12 months. Six eyes (30%) required topical treatment due to an intraocular pressure increase and 33% of phakic eyes at baseline needed cataract surgery.

Conclusions : Intravitreal dexamethasone implant is an effective and safe option for the treatment of DME on an as needed basis and can offer a valid alternative to anti-VEGF therapy with lower number of treatments.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×